ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2308건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2203 | Withdrawn | A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19 | COVID-19 | Drug: BRII-196 and BRII-198 Drug: Placebo |
Phase 2 | Brii Biosciences, Inc. | INDUSTRY | 0 | All | 18 Years | Investigative Site 1, Hong Kong, China |
| 2202 | Recruiting | A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19. | COVID-19 | Drug: Hymecromone tablets Other: Placebo |
Not Applicable | Shanghai Zhongshan Hospital | OTHER | 304 | All | 18 Years ~ 90 Years | Zhong Shan Hospital affiliated to Fudan University, Shanghai, Shanghai, China |
| 2201 | Active, not recruiting | A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals | SARS CoV 2 Infection | Drug: Sotrovimab | Phase 2 | Sophia Koo, M.D., Massachusetts General Hospital, Dana-Farber Cancer Institute, GlaxoSmithKline | OTHER | 93 | All | 18 Years | Massachusetts General Hospital, Boston, Massachusetts, United States Brigham and Women's Hospital, Boston, Massachusetts, United States Dana-Farber Cancer Institute, Boston, Massachusetts, United States |
| 2200 | Terminated | A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19 | COVID-19 | Biological: IBI314 Other: Placebo |
Phase 2 | Innovent Biologics (Suzhou) Co. Ltd. | INDUSTRY | 248 | All | 18 Years | Sobh, Anaheim, California, United States Long Beach Clinical Trials, LLC, Long Beach, California, United States Acclaim Clinical Research, San Diego, California, United States Herco Research Center, Inc., Coral Gables, Florida, United States Midland Florida Clinical Research Center - Inf. Disease/Infectiology, DeLand, Florida, United States Palm Springs Research Institute, Hialeah, Florida, United States Sweet Hope Research Specialty, Inc, Hialeah, Florida, United States The Clinical Research Institute LLC, Miami Gardens, Florida, United States Prestige Clinical Research Center Inc, Miami, Florida, United States Cordova Research Institute, LLC, Miami, Florida, United States Clinical Trials of Florida, LLC, Miami, Florida, United States Pembroke Clinical Trials, Pembroke Pines, Florida, United States Luminous Clinical Research LLC - South Florida Urgent Care - Infectious Diseases, Pembroke Pines, Florida, United States Palm Beach Research Center, West Palm Beach, Florida, United States Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States Excel Clinical Research - Internal Medicine, Las Vegas, Nevada, United States Temple University Health System - Temple Lung Center, Philadelphia, Pennsylvania, United States Zenos Clinical Research, Dallas, Texas, United States Epic Clinical Research, Lewisville, Texas, United States |
| 2199 | Terminated | A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19 | COVID-19 | Biological: IBI314(low dose) Biological: IBI314(high dose) Biological: IBI314(medium dose) Other: Placebo |
Phase 2 | Innovent Biologics (Suzhou) Co. Ltd. | INDUSTRY | 222 | All | 18 Years | The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China |
| 2198 | Completed | A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19) | Coronavirus Disease (COVID-19) | Biological: TAK-019 | Phase 3 | Takeda | INDUSTRY | 150 | All | 20 Years | Sumida Hospital, Sumida-ku, Tokyo, Japan PS Clinic, Fukuoka, Japan |
| 2197 | Completed | A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia | COVID-19 | Drug: Nafamostat Mesilate | Phase 2 | Chong Kun Dang Pharmaceutical | INDUSTRY | 104 | All | 18 Years | A108_02CVD2014 Site# 9, Barnaul, Russian Federation A108_02CVD2014 Site# 26, Krasnoyarsk, Russian Federation A108_02CVD2014 Site# 5, Moscow, Russian Federation A108_02CVD2014 Site# 8, Moscow, Russian Federation A108_02CVD2014 Site# 31, Ryazan, Russian Federation A108_02CVD2014 Site# 25, St. Petersburg, Russian Federation A108_02CVD2014 Site# 29, St. Petersburg, Russian Federation A108_02CVD2014 Site# 30, St. Petersburg, Russian Federation A108_02CVD2014 Site# 3, St. Petersburg, Russian Federation A108_02CVD2014 Site# 4, St. Petersburg, Russian Federation A108_02CVD2014 site#1, Ufa, Russian Federation |
